China-based biotech company I-Mab said on Friday that AbbVie has terminated a 2020 deal to co-develop and market I-Mab's lead cancer drug candidate lemzoparlimab.

I-Mab was founded in 2014 with the goal of taking advantage of the growing biologics market in China. The biotech opened its first U.S. outpost in Maryland in 2018, followed by the San Diego ...

Chinese biotechnology firm I-Mab is exploring options including a sale of the business amid takeover interest from other global drugmakers, according to people familiar with the matter.

ROCKVILLE, Md., June 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for ...

I-MAB Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024.The low is $100 issued by Deutsche Bank on August 5, 2024.

“MAB Discovery will now focus on further developing its proprietary mAbs with external partners.” The acquisition will be completed and the antibody generation unit transitioned at the end of ...

I-Mab is seeking a partner to jointly develop a cancer drug in the U.S. and Europe as the Chinese firm aims to replicate the success of last year’s $2.9 billion deal with AbbVie Inc., according ...

SHANGHAI and GAITHERSBURG, Md., March 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and ...

I-Mab has also signed a collaboration with neoX Biotech, which will provide access to up to 10 novel biologics programs, for cancer treatments using an artificial intelligence discovery platform.

One American Rifleman reader wrote in about his father's MAB Modele C, a French-made pistol built for personal protection use just after World War II.